Breaking News, Financial News

Financial Report: Amgen

Revenues up 10% in the quarter

Amgen
 
3Q Revenues: $4.7 billion (+10%)

3Q Earnings: $1.4 billion (+24%)

YTD Revenues: $13.7 billion (+6%)

YTD Earnings: $4.1 billion (+14%)

Comments: Neulasta/Neupogen sales were up 18% to $1.3 billion in the quarter. Enbrel sales increased 7% to $1.1 billion. Epogen sales were flat at $491 million. Xgeva/ Prolia sales increased 41% to $303 million. Sensipar/Mimpara sales increased 7% to $183 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters